YOU ARE HERE:
Salvage treatment news
page  of 5
 
Headline
Date
  Darunavir looking promising as companion for agents in new HIV drug classes
05.04.07
  Next generation NRTI, apricitabine (ATC), shows early promise
19.03.07
  CROI: Experimental 'salvage' integrase inhibitor, elvitegravir (GS-9137) appears potent at higher doses
06.03.07
  CROI: Maraviroc shows potent effect in highly treatment-experienced
28.02.07
  CROI: Integrase inhibitor raltegravir (MK-0518) doubles HIV suppression in treatment-experienced patients at 16 weeks
28.02.07
  After 48 weeks of study, and 24 weeks in the real world, darunavir continues to show staying power
21.12.06
  Prezista (darunavir) approved for treatment-experienced patients in Europe
15.12.06
  Pfizer announces expanded access programme for maraviroc
30.11.06
  HIV needs many more mutations to acquire resistance to darunavir
22.11.06
  TMC125 study highlights risk of staying on failing NNRTI regimen
16.11.06
  US researchers estimate HIV treatment will work for 24 years and cost £200k
10.11.06
  Genetically modified HIV shows early promise as a gene therapy viral vector
09.11.06
  Darunavir response did not differ by prior PI in POWER studies
09.10.06
  MK-0518: three-quarters of highly treated patients have undetectable viral load at 24 weeks
30.09.06
  Tibotec announces expanded access programme for new NNRTI TMC125
26.09.06
  Draft BHIVA treatment guidelines: respond by Monday September 4th
30.08.06
  Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered
18.08.06
  Merck launches expanded access programme for integrase inhibitor
17.08.06
  Selenium improves ART response in Nigerian randomised study
14.08.06
  Warning issued over bleeding within the skull in patients taking tipranavir
03.07.06

page  of 5